Nurulimab (Anti-CTLA-4 / CD152)
Nurulimab (Anti-CTLA-4 / CD152) is a monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4, CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.34 KD.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2859 |
| Sku # | A2859-1mg*25 |
| Pricing | 1mg*25, $2970.00 |